Form 4: Director Kent Kester Receives Turn Therapeutics Options

Director Kent Edward Kester was granted 83,334 stock options in Turn Therapeutics Inc. as part of the company's 2025 Omnibus Incentive Plan.

Summary

• Director Kent Edward Kester received a grant of 83,334 stock options on June 4, 2026.
• The options have an exercise price of $5.75 per share.
• The options are set to expire on June 4, 2036.
• Vesting occurs in twelve equal monthly installments starting June 30, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to the reporting person's continued service to the company.

Future Outlook

The options vest over a one-year period, indicating a commitment to the company's performance through mid-2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure leadership remains incentivized to drive long-term growth in the biotechnology sector.

Comparison to Industry Standards

• The use of a 12-month vesting schedule for director options is consistent with standard equity incentive plans for small-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

Turn Therapeutics, TTRX, Form 4, Insider Trading, Stock Options, Director Compensation